Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Press Release.

Novartis India Limited July 29, 2026 The Secretary BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 500 672 Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir / Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the press release titled "ChrysCapital Completes Acquisition of an Indian subsidiary of a Global Pharmaceutical Company", being issued by the Company. The press release will also be made available on the Company’s website at www.nilpharma.co.in. We request you to kindly take the above information on record. Yours sincerely, For Novartis India Limited Chandni Maru Company Secretary and Compliance Officer A60291 Encl as above: Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in Novartis India Limited ChrysCapital Completes Acquisition of an Indian subsidiary of a Global Pharmaceutical Company Dr. Vikas Gupta appointed as Managing Director and Chief Executive Officer of the organization. Mumbai, July 29, 2026: Novartis India Limited (NIL), a BSE-listed Indian pharmaceutical company previously held by the Swiss multinational, Novartis AG announced that ChrysCapital, one of the biggest private equity firms in India, acquired a controlling 70.68% stake in the organisation. The transaction marks a defining moment for the Indian pharmaceutical sector bringing one of India's longstanding pharmaceutical businesses under dedicated private equity ownership, with the ambition to build a leading branded-generics platform for the Indian market. NIL has a legacy spanning several decades and a portfolio of brands that are trusted both by healthcare professionals and patients. NIL operates across key therapeutic areas including pain management, calcium supplementation, gynaecology, neurosciences, and transplant immunology through brands such as Voveran®️, Calcium Sandoz®️, Tegrital®️ etc. Built on a strong foundation of scientific excellence, physician trust, and nationwide reach, NIL has played a meaningful role in improving healthcare outcomes for millions of patients across the country. To support the company's next phase of growth, NIL has appointed Dr. Vikas Gupta as MD and CEO. Further, Ramesh Ramadurai, Suchita Sharma and Shashank Sinha have joined as Independent Directors. Mr. Ramesh Ramadurai will be the Chairperson of the NIL board. Dr. Vikas Gupta, Managing Director and Chief Executive Officer, NIL, said: “NIL has earned its place in Indian healthcare over many decades. Today we begin a new and exciting chapter in NIL’s history. We carry forward decades of scientific rigour and physician trust - from that strong foundation and with ChrysCapital’s backing we have the resources and focus to grow our portfolio with purpose, reach more patients, and build on what this organisation has always stood for.” “A strong management team is central to any successful organisation, and NIL is fortunate to have Dr. Vikas Gupta at the helm - someone who brings both the experience and the vision this business needs. Combined with NIL's legacy brands and market standing, ChrysCapital believes the foundation for long-term value creation is firmly in place.” – Kshitij Sheth, Managing Director, ChrysCapital Advisors. The acquisition marks ChrysCapital's first majority-controlled investment in the Indian pharmaceutical sector and reflects the firm's strong conviction in the long-term growth potential of India's branded pharmaceuticals market. Building on a proven healthcare investment track record, ChrysCapital aims to leverage its sector expertise and extensive network to support the next phase of growth for NIL and strengthen its position as a leading pharmaceutical business. NIL will adopt a new name and corporate identity to celebrate the company’s separation from its previous owners and the beginning of a new era. ***END*** Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in Novartis India Limited About NIL Novartis India Limited (NIL) is a publicly listed pharmaceutical company in India and is part of ChrysCapital, India’s leading Private Equity firm. NIL has a long-standing presence in the Indian healthcare sector and is engaged primarily in the marketing, distribution, and sale of pharmaceutical products across key therapeutic areas. The company is listed on the Bombay Stock Exchange (BSE: 500672) and the National Stock Exchange of India (NSE: NOVARTIND). Headquartered in Mumbai, NIL focuses on bringing innovative and established medicines to patients and healthcare professionals throughout India. Media Contact media@nilpharma.co.in About ChrysCapital Founded in 1999, ChrysCapital is one of the largest and most established investment firms investing in India, with ~$8.5 billion raised across 10 private equity funds, a continuation fund, and a public markets fund. From its private equity funds, ChrysCapital has invested over $5.6 billion in more than 110 deals in sectors that it has been covering for 20+ years, and has realized almost $8 billion from 80+ exits. ChrysCapital counts some of the world’s largest sovereign wealth funds, public and private pension funds, insurance companies, endowments, foundations, and asset management companies as its investors. For further details, please visit - https://chryscapital.com/ Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in